Evotec
Maud BOUVIER currently serves as Associate Vice President of Discovery Business Development at Evotec, beginning in March 2024. Prior to this role, Maud BOUVIER was Vice President of Business Development at Sangamo Therapeutics France from 2018 to April 2024, focusing on out-licensing and in-licensing efforts for the Cell Therapy/CAR-Treg platform in autoimmune diseases. From December 2015 to 2018, Maud BOUVIER held the position of Vice President of Business Development at TxCell, where similar responsibilities were undertaken. Earlier experience includes roles at ERYTECH Pharma, where Maud BOUVIER served as Alliance Manager and Business Development Director from 2005 to 2015, and competitive intelligence strategies were managed. Maud BOUVIER holds a Corporate Finance Certificate from EDHEC Business School, a Master’s Degree in Management of Biotech Companies from Grenoble Graduate School of Business, and a PhD in Cell/Cellular and Molecular Biology from Grenoble University.
This person is not in the org chart
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.